BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

NCT07071844 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

162

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Trifluridine/tipiracil
DRUG: Bevacizumab

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborators

[object Object]